Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 2266 AL 2280

Iron dyshomeostasis in neuropsychiatric disorders

Cheng M, Ma J, Yang Y, Cao M, Zhang E, Feng B, Wang Q, Du Z.

Front Psychiatry. 2026 Apr 21;17:1771423. doi: 10.3389/fpsyt.2026.1771423. eCollection 2026.

Parkinson's disease drug therapies in the clinical trial pipeline: 2015-2024

Buff S, Pilcicka A, Pitzer K, Fiske B, Stott SR, McFarthing K.

J Parkinsons Dis. 2026 May 26:1877718X261454154. doi: 10.1177/1877718X261454154. Online ahead of print.

Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation

Stocchi F, Knecht M, Marjanovic I, Wach A, Kopra J, Kulisevsky J.

Neurol Ther. 2026 Jun;15(3):829-842. doi: 10.1007/s40120-026-00898-z. Epub 2026 Feb 22.

Neuroinflammation and Oxidative Stress in Parkinson's Disease, Alzheimer's Disease, and COVID-19: Microglia-Neutrophil Interaction

de Araújo AB, S Azul FVC, Carneiro YC, de Sousa CNS, de Vasconcelos SMM, Rios FJ, Leal LKAM.

ACS Omega. 2026 Jan 26;11(5):6922-6938. doi: 10.1021/acsomega.5c10397. eCollection 2026 Feb 10.

One world, one goal: Advocacy and policy for a unified Parkinson's response

Fothergill-Misbah N.

J Parkinsons Dis. 2026 May 7:1877718X261448383. doi: 10.1177/1877718X261448383. Online ahead of print.

Clinical utility of evoked potentials for programming subthalamic deep brain stimulation in Parkinsons disease

Hale B, Latorre A, Rocchi L, Rothwell J, Limousin P.

NPJ Parkinsons Dis. 2026 Jan 23;12(1):54. doi: 10.1038/s41531-026-01274-2.

Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease

Safarpour D, Brooks A, Smiley A, Katzka DA, Shprecher DR, Greene JG, Pahwa R, Troche MS, Kriegel Z, Peron EP, Bryant A, Fasano A, Ochoa M, Ramirez-Zamora A, Acevedo M, Blackwell GM, Pfeiffer RF, Parkman HP, Quigley EM, Cloud L.

J Parkinsons Dis. 2026 Feb;16(1):16-35. doi: 10.1177/1877718X251410503. Epub 2026 Jan 5.

Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis

Solla P, Masala C, Martinez G, Galiero R, Floris V, Ogana E, Canu V, Loy F, Ercoli T.

Brain Sci. 2026 May 21;16(5):545. doi: 10.3390/brainsci16050545.

Microglia heterogeneity and therapeutic strategies in Parkinson's disease

Tian J, Liu X, Wang Z, Shi X, Dai C, Yang L.

Front Immunol. 2026 Feb 5;17:1739341. doi: 10.3389/fimmu.2026.1739341. eCollection 2026.

Ferritin in ferroptosis: Implications for neurodegenerative diseases (Review)

Chen W, Tian H, Wei R, Chen X, Jia Y.

Int J Mol Med. 2026 May;57(5):119. doi: 10.3892/ijmm.2026.5790. Epub 2026 Mar 13.

Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies

Dzamko N.

CNS Drugs. 2026 Apr;40(4):509-522. doi: 10.1007/s40263-026-01275-y. Epub 2026 Feb 17.

The Ubiquitin-proteasome system in neuroinflammation and neurodegeneration: Molecular insights and therapeutic avenues

Guo Y, Wang N, Tao Z, Huang X, Yu W, Zeng J, Liu X, Chen S, Hua F, Wang X.

Int Immunopharmacol. 2026 Jun 15;179:116599. doi: 10.1016/j.intimp.2026.116599. Epub 2026 Apr 11.

The Multifaceted Roles of Eukaryotic Elongation Factor 1-Alpha-2 in Neurodevelopmental and Neurodegenerative Disorders

Khwanraj K, Prommahom A, Dharmasaroja P.

ScientificWorldJournal. 2026;2026(1):e4373377. doi: 10.1155/tswj/4373377.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias